Histone deacetylase inhibitor for NUT midline carcinoma

Pediatr Blood Cancer. 2015 Apr;62(4):715-7. doi: 10.1002/pbc.25350. Epub 2015 Jan 3.

Abstract

NUT Midline carcinoma (NMC) is a rare and invariably fatal poorly differentiated carcinoma characterized by chromosomal rearrangement involving the nuclear protein of the testis (NUT) gene. Current approaches do not provide durable response. We report a case of widely metastatic NMC in a 17-year-old female who, following an initial response to combination chemotherapy developed rapid disease progression. Treatment with vorinostat, a histone deacetylase inhibitor (HDACi) resulted in an objective response, yet she died in less than one year from initial diagnosis. This report shows a potentially promising activity of HDACi in the treatment of NMC that needs further exploration.

Keywords: NUT midline carcinoma; histone deacetylase inhibitor.

Publication types

  • Case Reports

MeSH terms

  • Adolescent
  • Carcinoma / diagnosis
  • Carcinoma / drug therapy*
  • Carcinoma / pathology
  • Female
  • Histone Deacetylase Inhibitors / administration & dosage*
  • Humans
  • Hydroxamic Acids / administration & dosage*
  • Mandibular Neoplasms / diagnosis
  • Mandibular Neoplasms / drug therapy*
  • Mandibular Neoplasms / pathology
  • Neoplasm Metastasis
  • Pleural Effusion, Malignant / diagnosis
  • Pleural Effusion, Malignant / drug therapy*
  • Pleural Effusion, Malignant / pathology
  • Vorinostat

Substances

  • Histone Deacetylase Inhibitors
  • Hydroxamic Acids
  • Vorinostat